Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lenvatinib vs sorafenib in unresectable hepatocellular carcinoma (first-line)
jRCT2080222067Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Overall survival (OS). Started Apr 2013; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080222067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222067.